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Abstract
Background
Smoking is a well-established cause of lung cancer and there is strong evidence that smok-
ing also increases the risk of several other cancers. Alcohol consumption has been inconsis-
tently associated with cancer risk in observational studies. This mendelian randomisation
(MR) study sought to investigate associations in support of a causal relationship between
smoking and alcohol consumption and 19 site-specific cancers.
Methods and findings
We used summary-level data for genetic variants associated with smoking initiation (ever
smoked regularly) and alcohol consumption, and the corresponding associations with lung,
breast, ovarian, and prostate cancer from genome-wide association studies consortia,
including participants of European ancestry. We additionally estimated genetic associations
with 19 site-specific cancers among 367,643 individuals of European descent in UK Biobank
who were 37 to 73 years of age when recruited from 2006 to 2010. Associations were con-
sidered statistically significant at a Bonferroni corrected p-value below 0.0013. Genetic pre-
disposition to smoking initiation was associated with statistically significant higher odds of
lung cancer in the International Lung Cancer Consortium (odds ratio [OR] 1.80; 95% confi-
dence interval [CI] 1.59–2.03; p = 2.26 × 10−21) and UK Biobank (OR 2.26; 95% CI 1.92–
2.65; p = 1.17 × 10−22). Additionally, genetic predisposition to smoking was associated with
statistically significant higher odds of cancer of the oesophagus (OR 1.83; 95% CI 1.34–
2.49; p = 1.31 × 10−4), cervix (OR 1.55; 95% CI 1.27–1.88; p = 1.24 × 10−5), and bladder
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(OR 1.40; 95% CI 1.92–2.65; p = 9.40 × 10−5) and with statistically nonsignificant higher
odds of head and neck (OR 1.40; 95% CI 1.13–1.74; p = 0.002) and stomach cancer (OR
1.46; 95% CI 1.05–2.03; p = 0.024). In contrast, there was an inverse association between
genetic predisposition to smoking and prostate cancer in the Prostate Cancer Association
Group to Investigate Cancer Associated Alterations in the Genome consortium (OR 0.90;
95% CI 0.83–0.98; p = 0.011) and in UK Biobank (OR 0.90; 95% CI 0.80–1.02; p = 0.104),
but the associations did not reach statistical significance. We found no statistically signifi-
cant association between genetically predicted alcohol consumption and overall cancer (n =
75,037 cases; OR 0.95; 95% CI 0.84–1.07; p = 0.376). Genetically predicted alcohol con-
sumption was statistically significantly associated with lung cancer in the International Lung
Cancer Consortium (OR 1.94; 95% CI 1.41–2.68; p = 4.68 × 10−5) but not in UK Biobank
(OR 1.12; 95% CI 0.65–1.93; p = 0.686). There was no statistically significant association
between alcohol consumption and any other site-specific cancer. The main limitation of this
study is that precision was low in some analyses, particularly for analyses of alcohol con-
sumption and site-specific cancers.
Conclusions
Our findings support the well-established relationship between smoking and lung cancer
and suggest that smoking may also be a risk factor for cancer of the head and neck, oesoph-
agus, stomach, cervix, and bladder. We found no evidence supporting a relationship
between alcohol consumption and overall or site-specific cancer risk.
Author summary
Why was this study done?
• Tobacco smoking and alcoholic beverage consumption are common addictive behav-
iours and important risk factors for mortality.
• Observational evidence has shown that smoking is a risk factor for cancers of the lung,
bladder, kidney, gastrointestinal tract, and cervix, but uncertainty persists about the
causal role of smoking for the development of other cancers.
• The causal role of alcohol consumption for site-specific cancers is uncertain, as available
evidence originates from observational studies which are susceptible to confounding
and reverse causation bias.
What did the researchers do and find?
• Using the mendelian randomisation (MR) design, we found that genetic predisposition
to smoking is associated with a statistically significant increased risk of cancer of the
lung, oesophagus, cervix, and bladder and with a statistically nonsignificant increased
risk of head and neck and stomach cancer at the Bonferroni-corrected significance
threshold.
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• Genetically predicted alcohol consumption was statistically significantly positively asso-
ciated with lung cancer but not with any other site-specific cancer or overall cancer.
What do these findings mean?
• In this study, we observed a relationship between smoking and lung cancer, as well as
evidence that smoking may also be a risk factor for cancer of the head and neck, oesoph-
agus, stomach, cervix, and bladder.
• We found no evidence supporting a relationship between alcohol consumption and
overall or site-specific cancer risk.
Introduction
Tobacco smoking and alcoholic beverage consumption are common addictive behaviours and
important causes of mortality [1–3]. The causal link between smoking and risk of lung cancer
is well established [4,5]. Strong experimental and observational evidence also indicates that
smoking is a risk factor for cancers of the bladder, kidney, gastrointestinal tract (head and
neck, oesophagus, stomach, colorectum, pancreas, and liver) and cervix [4–8], but uncertainty
persists about the causal role of smoking for the development of other cancers.
Observational data on alcohol consumption in relation to various cancers are contrasting
[7–14]. Alcohol consumption has been reported to be positively associated with risk of cancers
of the head and neck, oesophagus, stomach, liver, and breast [7,9,12–14] but inversely associ-
ated with kidney cancer [9,11] and non-Hodgkin lymphoma [9,12]. With regard to colorectal
cancer, a recent meta-analysis of 16 cohort studies showed that heavy alcohol consumption
was associated an increased risk of colorectal cancer, whereas light-to-moderate drinking was
associated with a decreased risk [10]. Given that much of the current evidence originates from
observational epidemiological studies, the causal nature of these findings needs assessment.
This is particularly important in the context of these addictive health behaviours, which can be
open to confounding by factors such as other destructive health behaviours and socioeconomic
status.
A recent meta-analysis of genome-wide association studies identified a number of single-
nucleotide polymorphisms (SNPs) associated with smoking and alcohol consumption [15].
Those SNPs can be used as instruments for these exposures in mendelian randomisation (MR)
analyses to infer causality. The MR technique is based on Mendel’s law of independent assort-
ment, which states that the inheritance of one characteristic is independent of the inheritance
of another. Thus, levels of the exposure predicted by the SNPs are usually independent of
other exposures, thereby reducing confounding in MR studies. In addition, the MR study
design avoids reverse causality because disease development cannot affect genotype.
The primary aim of this study was to use MR to examine the associations of smoking and
alcohol consumption with 19 site-specific cancers using data from four large-scale genome-
wide association studies consortia and UK Biobank. In complementary analyses, we assessed
the associations of genetically predicted smoking and alcohol consumption with overall cancer
in UK Biobank to determine the overall impact of smoking and alcohol from a public health
perspective.
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Methods
Outcome data sources
Publicly available summary-level data for lung, breast, ovarian, and prostate cancer were
obtained respectively from the International Lung Cancer Consortium (11,348 cases and
15,861 controls) [16], the Breast Cancer Association Consortium (122,977 cases and 105,974
controls) [17], the Ovarian Cancer Association Consortium (25,509 cases and 40,941 controls)
[18], and the Prostate Cancer Association Group to Investigate Cancer Associated Alterations
in the Genome consortium (79,148 cases and 61,106 controls) [19]. All participants included
in the consortia were of European ancestry and came from European and North American
countries and Australia. The lung cancer consortium included both women and men, whereas
the breast and ovarian cancer consortia included women only and the prostate cancer consor-
tium men only. Data from the consortia were extracted through the MR-Base platform [20].
In addition, we estimated genetic associations with 19 site-specific cancers (with at least 400
cases) and overall cancer in UK Biobank, a cohort study of about 500,000 adults (37 to 73 years
of age at baseline) recruited between 2006 and 2010 [21]. In the current analyses, we included
367,643 UK Biobank participants of European descent after exclusion of participants with other
ethnicities (to reduce population stratification bias), those with relatedness of third degree or
higher, excess heterozygosity, and low genotype call rate. Cancer cases were ascertained until
March 31, 2017, and were defined based on data from national registries (International Classifi-
cation of Diseases, 9th and 10th revision codes) and self-reported information verified by inter-
view with a nurse (S1 Table). We calculated beta coefficients and standard errors of the genetic
associations with cancer using logistic regression, with adjustment for age, sex, and 10 genetic
principal components. The UK Biobank study was approved by the North West Multicenter
Research Ethics Committee. All participants provided written informed consent. The present
analyses were approved by the Swedish Ethical Review Authority.
Genetic instruments
Instrumental variables for the exposures were selected from a meta-analysis of genome-wide
association studies with a total of 1,232,091 individuals of European descent in the analysis of
smoking initiation (i.e., probability of ever smoked regularly) and 941,280 individuals of Euro-
pean descent in the analysis of alcohol consumption [15]. A total of 378 and 99 conditionally
independent SNPs associated with smoking initiation and alcohol consumption (log-trans-
formed alcoholic drinks per week), respectively, at the genome-wide significance threshold
(p< 5 × 10−8) were identified [15]. Linkage disequilibrium (defined as R2 > 0.1) between
SNPs was assessed using LDlink [22] and was detected among 16 SNP pairs for smoking initia-
tion and among four SNP pairs for alcohol consumption. The SNP with the weakest associa-
tion with the exposure was removed. SNPs that were unavailable in the outcome datasets were
replaced by a suitable proxy (minimum linkage disequilibrium R2 = 0.8) where available. Our
genetic instruments comprised between 346 and 361 independent SNPs for smoking initiation
and between 89 and 94 independent SNPs for alcohol consumption. The SNPs explained 2.3%
and 0.2%–0.3% of the variation in smoking initiation and alcohol consumption, respectively
[15]. The genetic instruments were strongly associated with the exposures in UK Biobank,
with an F statistic from regression of the exposure on the variants of about 75 for smoking ini-
tiation and 19–29 for alcohol consumption. The two exposures were moderately genetically
correlated (rg = 0.36) [15]. The effect sizes are expressed per standard deviation increase in the
exposure [15]. For smoking, this was calculated from the weighted average prevalence of ever
smokers across the studies included in the meta-analysis [15].
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Statistical analysis
The principal analyses were conducted using the inverse-variance weighted approach (under a
multiplicative random-effects model), which provides the most precise estimates but assumes
that all SNPs are valid instrumental variables [23]. In sensitivity analyses, the following
approaches were applied: (1) multivariable MR analysis (inverse-variance weighted method)
with smoking adjusted for alcohol consumption and vice versa; (2) weighted median method,
which provides a causal estimate if at least 50% of the weight in the analysis comes from valid
instrumental variables [23]; (3) contamination mixture method, which performs MR robustly
and efficiently in the presence of invalid instrumental variables [24]; (4) MR pleiotropy resid-
ual sum and outlier (MR-PRESSO) method, which can detect and adjust for horizontal pleiot-
ropy by outlier removal [25]; and (5) MR-Egger regression method, which can detect and
adjust for directional pleiotropy but has low precision [23]. The mrrobust [26], Mendelian-
Randomization [27], and MRPRESSO [25] packages were used for the statistical analyses. The
reported odds ratios (OR) are per one standard deviation increase in the prevalence of smok-
ing initiation and per standard deviation increase in log-transformed alcoholic drinks per
week. We calculated the power at different ORs for each cancer site [28]. All statistical tests
were 2-tailed. Associations were considered statistically significant at a Bonferroni corrected
p-value below 0.0013 (correcting for 2 exposures and 19 outcomes).
Protocol
There was no formal predefined protocol or prospective analysis plan for this study. The MR
analyses of genetic predisposition to smoking and alcohol consumption in relation to overall
and site-specific cancers in UK Biobank were initiated in August 2019. Following peer review,
we (i) conducted MR analyses of smoking and alcohol consumption in relation to lung, breast,
ovarian, and prostate cancer using publicly available data from international consortia for
these cancers; (ii) defined the analysis of site-specific cancer as the primary analysis and
applied Bonferroni correction to site-specific cancers; (iii) calculated statistical power for each
site-specific cancer; and (iv) performed a complementary analysis using the contamination
mixture method.
This study is reported as per the Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) guideline (S1 Checklist).
Results
In analyses using consortia data, we had 80% power at a significance level of 0.05 to detect an
OR ranging from 1.05 (for breast cancer) to 1.25 (for lung cancer) for smoking initiation, and
a corresponding OR ranging from 1.28 to 1.90 for alcohol consumption (S2 Table). Relatively
strong magnitude of associations was necessary to detect significant ORs in site-specific cancer
analyses based on UK Biobank data, particularly for alcohol consumption (S2 Table).
Genetic predisposition to smoking initiation was associated with a statistically significant
higher odds of lung cancer in the International Lung Cancer Consortium (OR 1.80; 95% confi-
dence interval [CI] 1.59–2.03; p = 2.26 × 10−21) and UK Biobank (OR 2.26; 95% CI 1.92–2.65;
p = 1.17 × 10−22) (Fig 1). Additionally, genetic predisposition to smoking was associated with
statistically significantly higher odds of cancer of the oesophagus (OR 1.83; 95% CI 1.34–2.49;
p = 1.31 × 10−4), cervix (OR 1.55; 95% CI 1.27–1.88; p = 1.24 × 10−5), and bladder (OR 1.40;
95% CI 1.92–2.65; p = 9.40 × 10−5) and with statistically nonsignificant higher odds of head
and neck (OR 1.40; 95% CI 1.13–1.74; p = 0.002) and stomach cancer (OR 1.46; 95% CI 1.05–
2.03; p = 0.024) (Fig 1). In contrast, there was a statistically nonsignificant inverse association
between genetic predisposition to smoking and prostate cancer in the Prostate Cancer
PLOS MEDICINE Smoking, alcohol, and cancer
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Association Group to Investigate Cancer Associated Alterations in the Genome consortium
(OR 0.90; 95% CI 0.83–0.98; p = 0.011) and in UK Biobank (OR 0.90; 95% CI 0.80–1.02;
p = 0.104) (Fig 1). Results were consistent in sensitivity analyses (S3 Table). Genetic predispo-
sition to smoking initiation was associated with a statistically significant higher odds of both
lung adenocarcinoma and squamous cell lung cancer but was not associated with significantly
higher odds of oestrogen receptor positive or negative breast tumours or with any subtype of
non-Hodgkin lymphoma or leukaemia (S4 Table).
Genetically predicted alcohol consumption was statistically significantly positively associ-
ated with lung cancer in the International Lung Cancer Consortium (OR 1.94; 95% CI 1.41–
2.68; p = 4.68 × 10−5) but not in UK Biobank (OR 1.12; 95% CI 0.65–1.93; p = 0.686) (Fig 2).
After adjustment for genetic predisposition to smoking using multivariable MR, the associa-
tion between genetically predicted alcohol consumption and lung cancer in the International
Lung Cancer Consortium was attenuated and nonsignificant (OR 1.75; 95% CI 1.23–2.49;
p = 0.002) (S5 Table). There was no statistically significant association between genetically pre-
dicted alcohol consumption and any other site-specific cancer (Fig 2). However, the precision
Fig 1. Associations of genetic predisposition to smoking initiation with site-specific cancers. ORs are per one standard deviation increase in probability of smoking
initiation (ever smoked regularly). Results are obtained from the random-effects inverse-variance weighted method. The I2 statistic quantifies the amount of
heterogeneity among estimates based on individual SNPs. BCAC, Breast Cancer Association Consortium; CI, confidence interval; ILCCO, International Lung Cancer
Consortium; OCAC, Ovarian Cancer Association Consortium; OR, odds ratio; PRACTICAL, Prostate Cancer Association Group to Investigate Cancer Associated
Alterations in the Genome consortium; SNP, single-nucleotide polymorphism.
https://doi.org/10.1371/journal.pmed.1003178.g001
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of the estimates was generally low and the ORs were above 1.50 for testicular, head and neck,
and oesophageal cancers and below 0.70 for leukaemia, non-Hodgkin lymphoma, melanoma,
and brain cancer (Fig 2). The ORs were consistently above 2 for testicular cancer in all sensitiv-
ity analyses, but none of the associations reached statistical significance (S5 Table). Genetically
predicted alcohol consumption was associated with statistically nonsignificant higher odds of
both lung adenocarcinoma and squamous cell lung cancer in the International Lung Cancer
Consortium but was not associated with any lung cancer subtype in UK Biobank, oestrogen
receptor positive or negative breast tumours, or any subtype of non-Hodgkin lymphoma or
leukaemia (S6 Table).
For overall cancer (n = 75,037 cases, also including cancers with<400 cases, in UK Bio-
bank) a statistically nonsignificant positive association was observed with genetic predisposi-
tion to smoking in the inverse-variance weighted analysis (OR 1.06; 95% CI 1.02–1.10;
p = 0.007), but the association was attenuated in the alcohol-adjusted analysis (OR 1.03; 95%
CI 0.98–1.08; p = 0.304) (S3 Table). Genetically predicted alcohol consumption was not associ-
ated with overall cancer (OR 0.95; 95% CI 0.84–1.07; p = 0.376) (S5 Table).
Fig 2. Associations of genetically predicted alcohol consumption with site-specific cancers. ORs are per one standard deviation increase of log-transformed alcoholic
drinks per week. Results are obtained from the multiplicative random-effects inverse-variance weighted method. The I2 statistic quantifies the amount of heterogeneity
among estimates based on individual SNPs. BCAC, Breast Cancer Association Consortium; CI, confidence interval; ILCCO, International Lung Cancer Consortium;
OCAC, Ovarian Cancer Association Consortium; OR, odds ratio; PRACTICAL, Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the
Genome consortium; SNP, single-nucleotide polymorphism.
https://doi.org/10.1371/journal.pmed.1003178.g002
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Discussion
In the present MR study, we systematically assessed the associations of genetically predicted
smoking and alcohol consumption with a broad range of cancer types. Our results showed
that genetic predisposition to smoking was associated with an increased risk of several cancers,
supporting a causal relationship as consistent with previous observational studies. Genetically
predicted alcohol consumption was positively associated with lung cancer in the International
Lung Cancer Consortium but was not statistically significantly associated with any other site-
specific cancer or overall cancer. However, the precision was low in the site-specific cancer
analyses and there were relatively strong but statistically nonsignificant positive associations of
genetically predicted alcohol consumption (ORs above 1.5) with testicular, head and neck, and
oesophageal cancer, as well as inverse associations (ORs below 0.7) with leukaemia, non-
Hodgkin lymphoma, melanoma, and brain cancer.
Both tobacco and alcohol are biologically plausible tumour-promoting behaviours. Tobacco
smoke can increase the risk of cancer through its content of carcinogens, such as nitrosamines,
polycyclic aromatic hydrocarbons, acrylamines, volatile organics, and cadmium [7]. The carci-
nogenic effect of smoking on lung cancer is well established, and our MR findings corroborate
the observational evidence that smoking is also a risk factor for cancers of the head and neck,
oesophagus, stomach, cervix, and bladder [4–7]. Smoking is the major risk factor for bladder
cancer, and it has been estimated that ever smoking accounts for about two thirds and one
third of all bladder cancer cases in men and women, respectively [6]. Conventional observa-
tional studies have further shown that smoking increases the risk of kidney, pancreatic, and
colorectal cancer [4,5,7]. Although we failed to detect significant associations of genetic predis-
position to smoking with those cancers, the associations were positive, with an OR of 1.28 for
kidney cancer, 1.15 for pancreatic cancer, and 1.10 for colorectal cancer. Similarly, smoking
has been found to have a protective effect on melanoma risk in multiple meta-analyses, and
although our estimate was in this direction (OR 0.92), the association did not reach statistical
significance. Conventional observational studies have reported inconclusive results or no asso-
ciation of smoking with breast, ovarian, and brain cancers, melanoma, non-Hodgkin lym-
phoma, leukaemia, and multiple myeloma [4,5,7,29,30]. This MR study provided no evidence
of a causal association between smoking and those cancers. Furthermore, we found no support
of an inverse association between smoking and uterine cancer, consistent with findings from
most observational studies [5,7]. However, we found a statistically nonsignificant inverse asso-
ciation between smoking and prostate cancer. It is worth interpreting this result in light of the
fact that only 20% of the prostate cancer cases included in the prostate cancer consortium were
of advanced or highly aggressive disease [19]. Genetic association estimates specific to
advanced or highly aggressive prostate cancer were not publicly available. Our MR results for
prostate cancer, based largely on non-advanced disease, are consistent with the inverse associa-
tion between smoking and prostate cancer risk that has been reported specifically for localised
and low-grade disease in observational studies [31,32]. The inverse association may reflect
detection bias, such that smokers may be less likely to undergo prostate-specific antigen
screening and therefore are not diagnosed with prostate cancer until a late stage or not at all.
Alcohol consumption may increase the risk of cancer through its oxidised metabolite acet-
aldehyde, which is carcinogenic to humans [7]. Alcohol consumption might also lower cancer
risk by other mechanisms, such as increased insulin sensitivity through increased adiponectin
levels [33]. Red wine in particular has been suggested as potentially anticarcinogenic due to its
flavonoid content, which is both anti-inflammatory and antioxidative [34,35]. The present MR
findings are consistent with those of observational studies [6,7,9,12–14] and previous MR stud-
ies [36,37] indicating that alcohol consumption increases the risk of cancers of the head and
PLOS MEDICINE Smoking, alcohol, and cancer
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neck and oesophagus, although our estimates had low precision and did not reach statistical
significance. Alcohol drinking has also been reported to be associated with breast cancer risk
in a dose-response manner, with 8% to 12% increase in risk per 10 g/day increase of alcohol
consumption [9,13,14]. This MR study was underpowered to detect such a relatively modest
association. A harmful effect of heavy drinking on colorectal cancer has been suggested by
observational studies [10,12] as well as an MR study using the ALDH2 genotype as a marker of
alcohol exposure [38]. In contrast, light alcohol consumption has been shown to be unrelated
[12,14] or inversely [10] associated with colorectal cancer risk. If anything, our findings indi-
cated a positive association of alcohol consumption with colorectal cancer risk, but we were
unable to investigate a potential nonlinear relation. This study could not confirm an inverse
association of alcohol consumption with colorectal [10] and kidney [9,11] cancer and non-
Hodgkin lymphoma [9,12], but the association with non-Hodgkin lymphoma was in the same
direction. Our results agree with observational studies, which have shown no consistent rela-
tion between alcohol consumption and risk of leukaemia, melanoma, and brain cancer
[9,12,39], and with a previous MR study demonstrating no association between alcohol expo-
sure and prostate cancer incidence [40]. Likewise, data on alcohol consumption in relation to
testicular cancer risk are limited. The strong though nonsignificant positive association
between genetically predicted alcohol consumption and testicular cancer needs confirmation
by larger MR studies.
The inconsistent results for alcohol consumption and lung cancer between the International
Lung Cancer Consortium and UK Biobank may simply be a chance finding. Another possibility
is that the association of genetically predicted alcohol consumption with lung cancer may be due
to smoking rather than alcohol. While we were able to adjust for individual smoking behaviour
through multivariable MR analysis, increased alcohol consumption may lead to greater exposure
to cigarette smoke via passive smoking. This mechanism would be less represented in UK Bio-
bank due to the relatively low smoking rate in UK Biobank, and the smoking ban in the UK.
Key strengths of this study include the MR design, which mitigated bias due to confounding
and reverse causality, and the use of multiple instrumental variables for smoking and alcohol
consumption, which allowed sensitivity analyses to identify and adjust for pleiotropy. Another
strength is that the associations of smoking and alcohol consumption with cancer at many
sites could be assessed in a single large population of individuals of European descent. This
enabled comparison of the magnitude of the adverse impact of smoking and alcohol consump-
tion on different cancers while minimising population stratification bias.
A major limitation of this study is that the precision was low in some analyses. Analyses of
alcohol consumption in particular had low precision owing to low variance explained by the
SNPs, albeit with an F statistic above the conventional cutoff of 10. A low power may explain
the lack of statistically significant association of genetically predicted smoking and alcohol
consumption with certain site-specific cancers. For overall analyses, while overall cancer is a
combination of different malignancies that may have different underlying aetiologies, all can-
cers are known to share common underlying “hallmark” molecular and cellular aberrations.
Combining these malignancies together means that our endpoint is dependent on the charac-
teristics of the analytic sample and the relative prevalence of different cancer types. In particu-
lar, cancers with greater survival chances will be overrepresented in the case sample. However,
for most individuals, the choice to smoke cigarettes or drink alcohol is likely to be guided by
the impact on the overall risk of cancer, not any particular site-specific cancer. Hence, we
believe the results for overall cancer have direct relevance for public health. Another shortcom-
ing is that we were unable to assess possible U- or J-shaped relations between alcohol con-
sumption and cancer, or differential effects of specific alcoholic beverage types or drinking
patterns. A further potential limitation is that UK Biobank participants were included in both
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the exposure and outcome datasets, which might have introduced some bias in the MR esti-
mates in the direction of the estimates of observational studies. Nonetheless, only around one
third of participants in the genome-wide association studies of smoking and alcohol consump-
tion came from the UK Biobank study and the genetic instruments were relatively strongly
related to the exposures (F statistic >10), implying that bias from participant overlap is rela-
tively small [41]. An additional limitation is that smoking initiation is a binary exposure. An
MR estimate with a binary exposure and binary outcome is difficult to interpret as a specific
causal effect [42]. Furthermore, the MR estimate cannot simply be compared with the associa-
tion between self-reported smoking and cancer risk estimated by observational studies. How-
ever, even in this setting, MR estimates are unbiased under the null [43] and thus provide a
valid test of the causal null hypothesis even if the estimates do not reflect meaningful causal
parameters. Here, we expressed all estimates in terms of the association between genetically
predicted levels of smoking initiation and the outcome, rather than making claims about the
numerical magnitude of the causal effect. Our analyses included individuals of European
descent and therefore might not be generalisable to other populations.
These analyses broaden the evidence base for the harmful effect of cigarette smoking, which
has previously been demonstrated for most cardiovascular diseases [44,45], type 2 diabetes
[46], and bone fracture [47]. Those findings along with results of the present study provide fur-
ther evidential support for public health interventions to reduce cigarette smoking initiation in
the population, and suggest that these strategies will have an important impact on lessening
the burden of major diseases, and of cancer in particular.
Conclusions
The results of this study support the well-established relationship between smoking and lung
cancer, and suggest that smoking may also be a risk factor for cancer of the head and neck,
oesophagus, stomach, cervix, and bladder. We found no evidence in support of a relationship
between alcohol consumption and overall cancer risk, but associations between alcohol con-
sumption and risk of site-specific cancer should be further investigated.
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